DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have been given an average recommendation of “Moderate Buy” by the five research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $12.00.

A number of equities analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of DiaMedica Therapeutics in a research note on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Friday, July 17th. Finally, Wall Street Zen upgraded DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th.

Institutional Trading of DiaMedica Therapeutics

Hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. acquired a new stake in DiaMedica Therapeutics in the 3rd quarter worth $27,000. Bank of America Corp DE lifted its stake in shares of DiaMedica Therapeutics by 3,710.3% in the second quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock valued at $33,000 after buying an additional 8,274 shares during the period. Farther Finance Advisors LLC bought a new stake in shares of DiaMedica Therapeutics in the fourth quarter valued at about $34,000. JPMorgan Chase & Co. acquired a new stake in DiaMedica Therapeutics during the second quarter worth about $49,000. Finally, Invesco Ltd. acquired a new stake in DiaMedica Therapeutics during the second quarter worth about $54,000. 10.12% of the stock is owned by institutional investors.

DiaMedica Therapeutics Trading Up 1.6%

Shares of DMAC stock opened at $6.45 on Wednesday. DiaMedica Therapeutics has a 1-year low of $5.14 and a 1-year high of $10.42. The company has a market capitalization of $347.82 million, a price-to-earnings ratio of -8.96 and a beta of 1.01. The stock’s fifty day simple moving average is $6.91 and its 200-day simple moving average is $6.76.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.01. On average, sell-side analysts predict that DiaMedica Therapeutics will post -0.84 EPS for the current year.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.